Treatment of Erosive Gastritis and Duodenitis
The primary treatment for erosive gastritis and duodenitis is Helicobacter pylori eradication therapy when H. pylori is present (which occurs in approximately 47-100% of cases), using bismuth quadruple therapy as first-line treatment, combined with proton pump inhibitors and discontinuation of NSAIDs if applicable.
Initial Diagnostic Approach
The critical first step is determining H. pylori status through at least two positive tests (urease, histology, or serology) 1. This is essential because:
- H. pylori prevalence in erosive duodenitis approaches 100% in some studies 1
- However, erosive gastritis shows more variable H. pylori positivity (47% in one cohort) 2
- NSAID use is a common alternative etiology, particularly when H. pylori is absent 2
Treatment Algorithm
When H. pylori is Present
First-line therapy should be bismuth quadruple therapy 3. This regimen is preferred because:
- It avoids clarithromycin resistance issues that have reduced triple therapy success rates from 90% to much lower levels
- It maintains acceptable efficacy even with metronidazole-resistant strains
- All major consensus guidelines (ACG, European, and others) recommend this as optimal first-line treatment 3
Alternative first-line option: Concomitant 4-drug therapy (PPI + clarithromycin + amoxicillin + metronidazole) when bismuth is unavailable, particularly in areas of high clarithromycin resistance 3.
Specific effective regimen demonstrated: One-week therapy with omeprazole 20 mg twice daily plus two antibiotics (amoxicillin 1g twice daily + clarithromycin 500 mg twice daily, or substitute metronidazole 500 mg twice daily) achieved 86% eradication rates and 79% erosion healing 1.
Critical Treatment Principle
H. pylori eradication is the only variable that correlates with erosion healing (odds ratio 10; P < 0.01) 1. When eradication succeeds, erosion healing occurs in 86% of cases versus only 37% when eradication fails 1.
When H. pylori is Absent
For H. pylori-negative erosive gastritis/duodenitis:
- Discontinue NSAIDs immediately if being used 2
- PPI therapy as primary treatment
- Consider gastro-protective agents (sucralfate, misoprostol)
- Address duodenogastric reflux if present 4
Second-Line Therapy (If First-Line Fails)
If initial eradication fails, resistance to clarithromycin, levofloxacin, and/or metronidazole is likely. Avoid previously used antibiotics 3.
Second-line options:
- Bismuth quadruple therapy (if not used first-line)
- Levofloxacin triple therapy (depending on suspected resistance patterns)
- Reserve rifabutin-based triple therapy or high-dose dual amoxicillin-PPI therapy for subsequent attempts 3
Important Clinical Considerations
Common pitfall: Erosive duodenitis developing after successful H. pylori eradication occurs in 43% of patients 5. This is actually a favorable sign indicating successful eradication, not treatment failure. These patients remain asymptomatic with good prognosis and require no additional treatment 5.
Duration and follow-up:
- Repeat endoscopy and breath test 1 month after completing therapy 1
- Confirm sustained eradication at 6 months 1
- Histological improvement in gastric antrum and body occurs when eradication is achieved 1
Rare but critical consideration: In patients with atypical presentations (elderly, weight loss, persistent symptoms despite treatment), consider malignancy including metastatic disease, as erosive gastritis can rarely be a presentation of invasive lobular breast carcinoma 6.
The evidence strongly supports treating erosive duodenitis as a variant of duodenal ulcer disease requiring H. pylori eradication therapy 1, while erosive gastritis requires individualized assessment based on H. pylori status and NSAID exposure 2.